Surveillance of the Antimicrobial Susceptibility of &lt;i&gt;Neisseria gonorrhoeae&lt;/i&gt; Isolates Collected in Changsha, China from 2003 to 2015

Peng, Ting; Lin, Haixin; Liu, Qinglin; Yang, Junan; Cao, Wei; Ding, Hui; Tang, Lingli

doi:10.7883/yoken.jjid.2016.522

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the EU/EEA, resistance to extended-spectrum cephalosporins remained stable in 2016 with a decrease in the proportion of highly resistant isolates to cefixime (≥0.5 mg/L). However, a reduction in the proportion of isolates highly susceptible to ceftriaxone was observed, which has also been reported from other countries, e.g., China [ 19 ] (Changsha 2003–2015 [ 20 ], Shandong 2007–2014 [ 21 ]) and Argentina (2012–2013) [ 22 ] highlighting decreasing ceftriaxone susceptibility in several settings globally.…”

Section: Discussionsupporting

confidence: 71%

Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016

et al. 2018

View full text Add to dashboard Cite

BackgroundThe European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) performs annual sentinel surveillance of Neisseria gonorrhoeae susceptibility to therapeutically relevant antimicrobials across the European Union/European Economic Area (EU/EEA). We present the Euro-GASP results from 2016 (25 countries), linked to patient epidemiological data, and compared with data from previous years.MethodsAgar dilution and minimum inhibitory concentration (MIC) gradient strip methodologies were used to determine the antimicrobial susceptibility (using EUCAST breakpoints) of 2660 N. gonorrhoeae isolates from 25 countries across the EU/EEA. Significance of differences compared with Euro-GASP results in previous years was analysed using Z-tests.ResultsNo isolates with resistance to ceftriaxone (MIC > 0.125 mg/L) were detected in 2016 (one in 2015). However, the proportion of isolates with decreased susceptibility to ceftriaxone (MICs from 0.03 mg/L to 0.125 mg/L) increased significantly (p = 0.01) from 2015 to 2016. There were 14 (0.5%) isolates with ceftriaxone MICs 0.125 mg/L (on the resistance breakpoint), of which one isolate was resistant to azithromycin and four showed intermediate susceptibility to azithromycin. Cefixime resistance was detected in 2.1% of isolates in 2016 compared with 1.7% in 2015 (p = 0.26) and azithromycin resistance in 7.5% in 2016 compared with 7.1% in 2015 (p = 0.74). Seven (0.3%) isolates from five countries displayed high-level azithromycin resistance (MIC≥256 mg/L) in 2016 compared with five (0.2%) isolates in 2015. Resistance rate to ciprofloxacin was 46.5% compared with 49.4% in 2015 (p = 0.06). No isolates were resistant to spectinomycin and the MICs of gentamicin remained stable compared with previous years.ConclusionsOverall AMR rates in gonococci in EU/EEA remained stable from 2015 to 2016. However, the ceftriaxone MIC distribution shifted away from the most susceptible (≤0.016 mg/L) and the proportion of isolates with decreased susceptibility to ceftriaxone increased significantly. This development is of concern as current European gonorrhoea management guideline recommends ceftriaxone 500 mg plus azithromycin 2 g as first-line therapy. With azithromycin resistance at 7.5%, the increasing ceftriaxone MICs might soon threaten the effectiveness of this therapeutic regimen and requires close monitoring.

show abstract

Section: Discussionsupporting

confidence: 71%

Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the period from 2000 to 2015, 5–10 % of Japanese isolates were resistant to at least one of the antimicrobials in the current dual therapy [37]. In the same period, China also reported an increasing number of isolates with decreased susceptibility to ceftriaxone and at least one with an azithromycin MIC of 1 mg l −1 [38]. The only genomic analysis from the West Pacific region came from a recent analysis by Lee et al .…”

Section: Genomic Insight Into Amr Gonococcusmentioning

confidence: 99%

Using genomics to understand antimicrobial resistance and transmission in Neisseria gonorrhoeae

Sánchez-Busó

Harris

2019

Microbial Genomics

View full text Add to dashboard Cite

Gonorrhoea infections are on the increase and strains that are resistant to all antimicrobials used to treat the disease have been found worldwide. These observations encouraged the World Health Organization to include Neisseria gonorrhoeae on their list of high-priority organisms in need of new treatments. Fortunately, concurrent resistance to both antimicrobials used in dual therapy is still rare. The fight against antimicrobial resistance (AMR) must begin from an understanding of how it evolves and spreads in sexual networks. Genome-based analyses have allowed the study of the gonococcal population dynamics and transmission, giving a novel perspective on AMR gonorrhoea. Here, we will review past, present and future treatment options for gonorrhoea and explain how genomics is helping to increase our understanding of the changing AMR and transmission landscape. This article contains data hosted by Microreact.

show abstract

Surveillance of the Antimicrobial Susceptibility of <i>Neisseria gonorrhoeae</i> Isolates Collected in Changsha, China from 2003 to 2015

Cited by 2 publications

References 18 publications

Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016

Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016

Using genomics to understand antimicrobial resistance and transmission in Neisseria gonorrhoeae

Contact Info

Product

Resources

About